Phenylephrine
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Phenylephrine: From Nasal Congestion to Nasal Cavity Disease
One-Sentence Summary
Phenylephrine is a well-established selective α1-adrenergic agonist, with published pharmacology literature describing its use for nasal congestion, hypotension, and asthma. The TxGNN model’s top prediction — Nasal Cavity Disease — largely reconfirms this already-known decongestant mechanism rather than proposing a genuinely novel indication, supported by 8 clinical trials and 8 publications, though most involve combination products or comparator drugs rather than phenylephrine monotherapy.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack’s regulatory license data (no marketing authorization on file); literature confirms established pharmacological use for nasal congestion, hypotension, and asthma (PMID 31145702) |
| Predicted New Indication | Nasal Cavity Disease |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L2 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed formal mechanism-of-action data (DrugBank MOA field) is not available in this evidence pack. However, the prediction’s own rationale confirms that phenylephrine is a selective α1-adrenergic agonist acting directly on nasal mucosal vascular smooth muscle, causing vasoconstriction and reducing mucosal congestion and swelling.
This mechanism is mechanistically identical to phenylephrine’s well-known, long-standing use as an over-the-counter nasal decongestant. The evidence pack’s own reasoning explicitly flags this: the “Nasal Cavity Disease” prediction should be understood as confirmation of an existing pharmacological application rather than a novel repurposing hypothesis. In other words, the TxGNN model has correctly identified a relationship that is already grounded in decades of clinical practice, rather than surfacing new therapeutic potential.
Supporting evidence includes combination nasal products such as Co-phenylcaine and Kovanaze (phenylephrine/tetracaine), and topical formulations like Polydexa (phenylephrine-containing), which are used clinically for nasal decongestion, procedural anesthesia, and rhinosinusitis. These real-world products reinforce the plausibility of the mechanism, though most trial and literature evidence involves phenylephrine as one component of a combination product rather than as a standalone intervention.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03228914 | Phase 4 | Completed | 20 | Compared topical oxymetazoline vs. epinephrine (both α-agonists) for blood loss/surgical visualization in endoscopic sinus surgery; mechanistic analog, not phenylephrine itself |
| NCT00562120 | Phase 2 | Completed | 21 | Tested an H3-receptor antagonist against nasal allergen-induced congestion; phenylephrine not the study drug |
| NCT04104789 | Phase 2 | Withdrawn | 0 | Kovanaze (phenylephrine/tetracaine nasal spray) vs. articaine for maxillary dental pulpal anesthesia — direct phenylephrine application, withdrawn for insufficient recruitment |
| NCT06443255 | Phase 3 | Completed | 16 | Compared cocaine, lidocaine/xylometazoline, and saline for intranasal analgesia before awake nasotracheal intubation; phenylephrine not tested |
| NCT02993770 | N/A | Unknown | 120 | Compared endoscopic vs. external dacryocystorhinostomy for nasolacrimal duct obstruction; no direct phenylephrine arm |
| NCT03962634 | Phase 2 | Terminated | 3 | Same Kovanaze vs. articaine design as NCT04104789; direct phenylephrine test, terminated early (n=3) |
| NCT06457100 | Phase 1/2 | Active, not recruiting | 60 | Esmolol vs. lidocaine infusion for recovery quality after functional endoscopic sinus surgery; phenylephrine only a background/comparator agent |
| NCT03380715 | N/A | Completed | 106 | Co-phenylcaine (contains phenylephrine) nasal spray vs. nebulization before nasoendoscopy — combination product with direct clinical relevance |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15854186 | 2005 | RCT | Int J Clin Pract | Double-blind RCT (n=98): cophenylcaine (contains phenylephrine) spray vs. placebo before flexible nasendoscopy; minimal pain/discomfort in both groups, no significant difference |
| 40899890 | 2025 | RCT | Vestnik Otorinolaringologii | Experimental/clinical evaluation of Polydexa spray with phenylephrine in acute rhinosinusitis, assessing safety and efficacy of the topical combination product |
| 25133491 | 2014 | Cohort | PLoS One | Triple-blind trial on topical tranexamic acid for bleeding/surgical field quality during FESS in chronic rhinosinusitis |
| 37970776 | 2023 | Review | Vestnik Otorinolaringologii | Pathogenetic approach to treatment of inflammatory nose/paranasal sinus disease, discussing decongestant mechanisms |
| 1375136 | 1992 | In vitro/mechanistic | Clin Otolaryngol Allied Sci | Investigated effects of nasal drugs, including phenylephrine, on ciliary beat frequency in vitro |
| 37184554 | 2023 | Not yet classified | Vestnik Otorinolaringologii | Endoscopic evaluation of nasal mucosa after topical therapy with Polydexa (contains phenylephrine) in granulomatosis with polyangiitis |
| 9780066 | 1998 | Not yet classified | Int J Pediatr Otorhinolaryngol | Acoustic rhinometric evaluation of nasal cavity/nasopharynx geometry after adenotonsillectomy (background nasal physiology) |
| 7378007 | 1980 | Not yet classified | Arch Ophthalmol | Case report describing toxicity following cocaine and intranasal phenylephrine during dacryocystorhinostomy — a safety signal, not efficacy evidence |
EU Market Information
No marketing authorization is currently on file for this drug in this jurisdiction (market status: Not Marketed, 0 licenses recorded).
Safety Considerations
Please refer to the SmPC for safety information. Key warnings, contraindications, and drug interaction data are not currently available in this evidence pack (DDI query status: not found).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The top prediction (Nasal Cavity Disease) is supported by L2-level evidence, including a Phase 3 completed trial and an RCT-tier publication, but the majority of the underlying evidence involves combination products (Co-phenylcaine, Kovanaze, Polydexa) or comparator drugs rather than phenylephrine monotherapy. Critically, this prediction largely reconfirms phenylephrine’s already-known decongestant pharmacology rather than identifying a genuinely new therapeutic use, which limits its value as a repurposing candidate.
To proceed, the following is needed:
- TFDA/regulatory-equivalent warnings and contraindications (currently a Blocking data gap — required before any safety pre-screening)
- Formal mechanism-of-action documentation (DrugBank MOA is currently a data gap)
- Clarification on whether “Nasal Cavity Disease” should be treated as a repurposing candidate at all, given it substantially overlaps with phenylephrine’s established decongestant use
- Trial-level data isolating phenylephrine monotherapy effects from combination-product formulations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.